StageZero Life Sciences (GNWSF) Stock Price, News & Analysis

Company Overview

StageZero Life Sciences Ltd. is a healthcare technology company focused on developing and commercializing molecular diagnostic solutions for the early detection and management of disease. The company uses gene-expression analysis and other molecular technologies to identify biological signals in blood and support more accessible testing.

Its principal product is the Aristotle test, a blood-based molecular diagnostic designed to screen for multiple types of cancer. StageZero has also described applications of its technology in cancer risk assessment, diagnostic support and personalized care. The company’s approach is intended to complement conventional screening and diagnostic procedures by helping identify potential disease at an earlier stage.

StageZero, formerly known as GeneNews Corporation, has pursued a business model that combines laboratory testing, digital healthcare services and physician-supported patient care. Its activities have included efforts to make testing available through healthcare providers and telehealth channels, with an emphasis on serving patients in North America and other markets where its services are authorized. The company is headquartered in Canada.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 26,719 shs
• Market Capitalization: $22.68 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: OTCMKTS:GNWSF
• CIK: 1454263
• Web: www.stagezerolifesciences.com
• Phone: 905-209-2030
• Fax: N/A
• Employees: 80
• Year Founded: 1998

Profitability

• EPS (Trailing Twelve Months): ($0.28)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.86 million
• Net Margins: -200.26%
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -165.13%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.15
• Quick Ratio: 1.08

Sales & Book Value

• Annual Sales: $4.15 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.02) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 62,995,000
• Free Float: N/A
• Market Cap: $22.68 million
• Optionable: Not Optionable
• Beta: 0.28